We are the Artful Dodgers of the globalised world, experts at ducking and diving - but even the Dodger gets caught in the end ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $512.52, indicating a +0.06% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 1.08%.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Google is diving deeper into voice AI, announcing the addition of its Chirp 3 speech-to-text and HD text-to-speech models to ...

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...

Analysts may not have crystal balls, but they’re pretty bullish on Vertex’s 2028 outlook, despite its rocky stock performance ...

After hours: March 21 at 7:13:50 PM EDT Loading Chart for VRTX ...